Journal
CURRENT PHARMACEUTICAL DESIGN
Volume 25, Issue 30, Pages 3248-3256Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1381612825666190816233755
Keywords
Disulfiram; cancer; molecular targets; drug delivery; clinical trials; anticancer agents
Categories
Funding
- National Natural Science Foundation of China [81872439, 31700780]
- China Postdoctoral Science Foundation [2018T110281, 2017M610201]
- National Cancer Institute [R21CA184788]
- National Institutes of Health [P30 CA022453]
- Karmanos
Ask authors/readers for more resources
Repurposing already approved drugs as new anticancer agents is a promising strategy considering the advantages such as low costs, low risks and less time-consumption. Disulfiram (DSF), as the first drug for anti-alcoholism, was approved by the U.S. Food and Drug Administration (FDA) over 60 years ago. Increasing evidence indicates that DSF has great potential for the treatment of various human cancers. Several mechanisms and targets of DSF related to cancer therapy have been proposed, including the inhibition of ubiquitin-proteasome system (UPS), cancer cell stemness and cancer metastasis, and alteration of the intracellular reactive oxygen species (ROS). This article provides a brief review about the history of the use of DSF in humans and its molecular mechanisms and targets of anticancer therapy, describes DSF delivery strategies for cancer treatment, summarizes completed and ongoing cancer clinical trials involving DSF, and offers strategies to better use DSF in cancer therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available